Role of mineralocorticoid receptor antagonists in cardiovascular disease

Circulation Research

Volumn 116, Issue 1, 2015, Pages 206-213

  Ferrario, Carlos M ^a   Schiffrin, Ernesto L ^b  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

heart failure; hypertension; kidney failure, chronic

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR;

ATHEROSCLEROSIS; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; HUMAN; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; HOMEOSTASIS; METABOLISM; PHYSIOLOGY;

ALDOSTERONE; ANIMALS; CARDIOVASCULAR DISEASES; HOMEOSTASIS; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECEPTORS, MINERALOCORTICOID;

EID: 84920854895     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.302706     Document Type: Review

References (120)

1. Wilcox JW, History JE. Nonsurgical resolution of mucoceles. J Oral Surg. 1978;36:478.
2. Addison T. On the Constitutional Local Effects of Disease of the Suprarenal Capsules. London, UK: P. Highley;1855.
3. Kuizinga MH, Cartland GF. Fractionation studies on adrenal cortical extract with notes on the distribution of biological activity among the crystalline and amorphous fractions. Endocrinology 1939;24:526-535.
4. Simpson SA, Tait JF. A quantitative method for the bioassay of the effect of adrenal cortical steroids on mineral metabolism. Endocrinology. 1952;50:150-161. doi:10.1210/endo-50-2-150.
5. Simpson SA, Tait JF, Bush IE. Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet. 1952;2:226-228.
6. Simpson SA, Tait JF, Wettstein A, Neher R, Von Euw J, Reichstein T. [Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism]. Experientia. 1953;9:333-335.
7. Simpson SA, Tait JF. The nature of the circulating hormones of the adrenal cortex in man. Arch Middx Hosp. 1953;3:209-218.
8. Tait JF, Simpson SA, Grundy HM. The effect of adrenal extract on mineral metabolism. Lancet. 1952;1:122-124.
9. Simpson SA, Tait JF, Wettstein A, Neher R, Von Euw J, Schindler O, Reichstein T. [Constitution of aldosterone, a new mineralocorticoid]. Experientia. 1954;10:132-133.
10. Schmidlin J, Anner G, Billeter JR, Wettstein A. [Synthesis in aldosteroneseries. I. Total synthesis of racemic aldosterone]. Experientia. 1955;11: 365-368.
11. Vischer E, Schmidlin J, Wettstein A. [Microbiological separation of racemic steroids; synthesis of d-aldosterone]. Experientia. 1956;12:50-52.
12. Giroud CJ, Saffran M, Schally AV, Stachenko J, Venning EH. Production of aldosterone by rat adrenal glands in vitro. Proc Soc Exp Biol Med. 1956;92:855-859.
13. Giroud CJ, Stachenko J, Venning EH. Secretion of aldosterone by the zona glomerulosa of rat adrenal glands incubated in vitro. Proc Soc Exp Biol Med. 1956;92:154-158.
14. Tait SA, Tait JF, Coghlan JP. The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function. Mol Cell Endocrinol. 2004;217:1-21. doi:10.1016/j.mce.2003.10.004.
15. Wintersteiner O, Vars HM, Pfiffner JJ. Chemical investigations of the cortical hormone of the adrenal gland. J Biol Chem 1934;105:100-101.
16. Mason H, Myers CS, Kendall EC. The chemistry of crystalline substances isolated from the suprarenal gland. J Biol Chem 1936;114:613-631.
17. Reichstein T. Uber cortin, da hormon der nebbennieren rinde (X. I. Mitteilung). Helv Chim Acta 1936;19:29-63.
18. Luetscher JA Jr, Neher R, Wettstein A. Isolation of crystalline aldosterone from the urine of patients with congestive heart failure. Experientia. 1956;12:22-23.
19. Genest J, Kuchel O, Nowaczynsli W. Classification of Hypermineralocorticoid Hypertension. In: Onesti G, Kim KI, Moyer JH, eds. Hypertension, Mechanisms and Management. New York and London: Grune & Stratton, Inc;1973:463-470.
20. Funder JW. Aldosterone action. Annu Rev Physiol. 1993;55:115-130. doi:10.1146/annurev.ph.55.030193.000555.
21. Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids. 2011;76:834-839. doi:10.1016/j.steroids.2011.02.015.
22. Viengchareun S, Le Menuet D, Martinerie L, Munier M, Pascual-Le Tallec L, Lombès M. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal. 2007;5:e012. doi:10.1621/nrs.05012.
23. Feldman RD, Gros R. Vascular effects of aldosterone: sorting out the receptors and the ligands. Clin Exp Pharmacol Physiol. 2013;40:916-921. doi:10.1111/1440-1681.12157.
24. Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis. 2003;166:345-349.
25. Schmidt BM, Montealegre A, Janson CP, Martin N, Stein-Kemmesies C, Scherhag A, Feuring M, Christ M, Wehling M. Short term cardiovascular effects of aldosterone in healthy male volunteers. J Clin Endocrinol Metab. 1999;84:3528-3533. doi:10.1210/jcem.84.10.6020.
26. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005;96:643-650. doi:10.1161/01.RES.0000159937.05502.d1.
27. Lösel R, Feuring M, Wehling M. Non-genomic aldosterone action: from the cell membrane to human physiology. J Steroid Biochem Mol Biol. 2002;83:167-171.
28. Lösel R, Schultz A, Boldyreff B, Wehling M. Rapid effects of aldosterone on vascular cells: clinical implications. Steroids. 2004;69:575-578. doi:10.1016/j.steroids.2004.05.005.
29. Wehling M. Specific, nongenomic actions of steroid hormones. Annu Rev Physiol. 1997;59:365-393. doi:10.1146/annurev.physiol.59.1.365.
30. Coutinho P, Vega C, Pojoga LH, Rivera A, Prado GN, Yao TM, Adler G, Torres-Grajales M, Maldonado ER, Ramos-Rivera A, Williams JS, Williams G, Romero JR. Aldosterone's rapid, nongenomic effects are mediated by striatin: a modulator of aldosterone's effect on estrogen action. Endocrinology. 2014;155:2233-2243. doi:10.1210/en.2013-1834.
31. Funder JW. Mineralocorticoids, glucocorticoids, receptors and response elements. Science. 1993;259:1132-1133.
32. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol. 1985;63:1522-1527.
33. Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, Challande P, Jaffe IZ, Labat C, Lacolley P, Jaisser F. Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension. 2014;63:520-526. doi:10.1161/HYPERTENSIONAHA.113.01967.
34. Lemarié CA, Simeone SM, Nikonova A, Ebrahimian T, Deschênes ME, Coffman TM, Paradis P, Schiffrin EL. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res. 2009;105:852-859. doi:10.1161/CIRCRESAHA.109.196576.
35. Briet M, Schiffrin EL. Vascular actions of aldosterone. J Vasc Res. 2013;50:89-99. doi:10.1159/000345243.
36. Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, Schiffrin EL. Tregulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension. 2012;59:324-330. doi:10.1161/HYPERTENSIONAHA.111.181123.
37. Leibovitz E, Ebrahimian T, Paradis P, Schiffrin EL. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. J Hypertens. 2009;27:2192-2200. doi:10.1097/HJH.0b013e328330a963.
38. McGraw AP, McCurley A, Preston IR, Jaffe IZ. Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications. Curr Atheroscler Rep. 2013;15:340. doi:10.1007/s11883-013-0340-x.
39. Schiffrin EL; Canadian Institutes of Health Research Multidisciplinary Research Group on Hypertension. Beyond blood pressure: the endothelium and atherosclerosis progression. Am J Hypertens. 2002;15:115S-122S.
40. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47:312-318. doi:10.1161/01.HYP.0000201443.63240.a7.
41. Jaffe IZ, Newfell BG, Aronovitz M, Mohammad NN, McGraw AP, Perreault RE, Carmeliet P, Ehsan A, Mendelsohn ME. Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest. 2010;120:3891-3900. doi:10.1172/JCI40205.
42. McGraw AP, Bagley J, Chen WS, Galayda C, Nickerson H, Armani A, Caprio M, Carmeliet P, Jaffe IZ. Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factordependent mechanism. J Am Heart Assoc. 2013;2:e000018. doi:10.1161/JAHA.112.000018.
43. Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension. 2005;46:1135-1139. doi:10.1161/01.HYP.0000184640.81730.22.
44. Liu S, Xie Z, Daugherty A, Cassis LA, Pearson KJ, Gong MC, Guo Z. Mineralocorticoid receptor agonists induce mouse aortic aneurysm formation and rupture in the presence of high salt. Arterioscler Thromb Vasc Biol. 2013;33:1568-1579. doi:10.1161/ATVBAHA.112.300820.
45. Schiffrin EL. The many targets of aldosterone. Hypertension. 2004;43:938-940. doi:10.1161/01.HYP.0000123573.60340.9b.
46. Schiffrin EL. Immune modulation of resistance artery remodelling. Basic Clin Pharmacol Toxicol. 2012;110:70-72. doi:10.1111/j.1742-7843.2011.00760.x.
47. Idris-Khodja N, Mian MOR, Paradis P, Schiffrin EL. Dual roles of adaptive immunity in hypertension. Eur Heart J. 2014;35:1238-1244.
48. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011;57:469-476. doi:10.1161/HYPERTENSIONAHA.110.162941.
49. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586-1593.
50. Ferrario CM, Smith R, Levy P, Strawn W. The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. Am J Med. Sci. 2002;323:17-24.
51. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;98:121-128. doi:10.1016/j.amjcard.2006.01.059.
52. Strawn WB, Ferrario CM. Angiotensin II AT1 receptor blockade normalizes CD11b+ monocyte production in bone marrow of hypercholesterolemic monkeys. Atherosclerosis. 2008;196:624-632. doi:10.1016/j. atherosclerosis.2007.06.024.
53. Keidar S, Hayek T, Kaplan M, Pavlotzky E, Hamoud S, Coleman R, Aviram M. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2003;41:955-963.
54. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004;109:2213-2220. doi:10.1161/01. CIR.0000127949.05756.9D.
55. Suzuki J, Iwai M, Mogi M, Oshita A, Yoshii T, Higaki J, Horiuchi M. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol. 2006;26:917-921. doi:10.1161/01.ATV.0000204635.75748.0f.
56. Irita J, Okura T, Manabe S, Kurata M, Miyoshi K, Watanabe S, Fukuoka T, Higaki J. Plasma osteopontin levels are higher in patients with primary aldosteronism than in patients with essential hypertension. Am J Hypertens. 2006;19:293-297. doi:10.1016/j.amjhyper.2005.08.019.
57. Irita J, Okura T, Jotoku M, Nagao T, Enomoto D, Kurata M, Desilva VR, Miyoshi K, Matsui Y, Uede T, Denhardt DT, Rittiling SR, Higaki J. Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. Am J Physiol Renal Physiol. 2011;301:F833-F844. doi:10.1152/ajprenal.00557.2010.
58. Jeong Y, Chaupin DF, Matsushita K, Yamakuchi M, Cameron SJ, Morrell CN, Lowenstein CJ. Aldosterone activates endothelial exocytosis. Proc Natl Acad Sci USA. 2009;106:3782-3787. doi:10.1073/pnas.0804037106.
59. Brown NJ, Vaughan DE, Fogo AB. Aldosterone and PAI-1: implications for renal injury. J Nephrol. 2002;15:230-235.
60. Alexandre J, Puddu PE, Simard C, Hof T, Sallé L, Guinamard R, Manrique A, Rouet R, Beygui F, Milliez P. Proarrhythmic effects of aldosterone during myocardial ischemia-reperfusion: implication of the sarcolemmal-KATP channels. J Cardiovasc Pharmacol. 2014;64:134-141. doi:10.1097/FJC.0000000000000097.
61. Beygui F, Collet JP, Benoliel JJ, Vignolles N, Dumaine R, Barthélémy O, Montalescot G. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006;114:2604-2610. doi:10.1161/CIRCULATIONAHA.106.634626.
62. Beygui F, Labbé JP, Cayla G, Ennezat PV, Motreff P, Roubille F, Silvain J, Barthélémy O, Delarche N, Van Belle E, Collet JP, Montalescot G. Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. Int J Cardiol. 2013;167:73-79. doi:10.1016/j.ijcard.2011.11.076.
63. Ivanes F, Susen S, Mouquet F, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J. 2012;33: 191-202. doi:10.1093/eurheartj/ehr176.
64. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13:9-20.
65. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003;24:261-271. doi:10.1210/er.2003-0001.
66. van Kats JP, van Meegen JR, Verdouw PD, Duncker DJ, Schalekamp MA, Danser AH. Subcellular localization of angiotensin II in kidney and adrenal. J Hypertens. 2001;19:583-589.
67. van Kats JP, Chai W, Duncker DJ, Schalekamp MA, Danser AH. Adrenal angiotensin: origin and site of generation. Am J Hypertens. 2005;18: 1104-1110. doi:10.1016/j.amjhyper.2005.02.005.
68. Schiffrin EL, Gutkowska J, Genest J. Effect of angiotensin II and deoxycorticosterone infusion on vascular angiotensin II receptors in rats. Am J Physiol. 1984;246:H608-H614.
69. Wehling M, Neylon CB, Fullerton M, Bobik A, Funder JW. Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells. Circ Res. 1995;76:973-979.
70. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004;109:2792-2800. doi:10.1161/01.CIR.0000131860.80444.AB.
71. Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, Marusic ET. Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology. 2005;146:973-980. doi:10.1210/en.2004-1130.
72. Yamada M, Kushibiki M, Osanai T, Tomita H, Okumura K. Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovasc Res. 2008;79:169-178. doi:10.1093/cvr/cvn064.
73. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, Jaffe IZ. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med. 2012;18:1429-1433. doi:10.1038/nm.2891.
74. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in strokeprone spontaneously hypertensive rats. Hypertension. 2004;43:1252-1257. doi:10.1161/01.HYP.0000128031.31572.a3.
75. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 2002;143:4828-4836. doi:10.1210/en.2002-220120.
76. CONN JW, LOUIS LH. Primary aldosteronism: a new clinical entity. Trans Assoc Am Physicians. 1955;68:215-231; discussion 231.
77. CONN JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3-17.
78. Steigler M, Reichstein T. Desoxycorticosterone (21-oxyprogesterone aus 5-3-oxy-atio cholensaure). Helv Chim Acta 1937;20:1164.
79. White PC, Mune T, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev. 1997;18:135-156. doi:10.1210/edrv.18.1.0288.
80. White PC, Mune T, Rogerson FM, Kayes KM, Agarwal AK. Molecular analysis of 11 beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Steroids. 1997;62:83-88.
81. White PC, Mune T, Rogerson FM, Kayes KM, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Pediatr Res. 1997;41:25-29. doi:10.1203/00006450-199704001-00158.
82. Mayes D, Furuyama S, Kem DC, Nugent CA. A radioimmunoassay for plasma aldosterone. J Clin Endocrinol Metab. 1970;30:682-685. doi:10.1210/jcem-30-5-682.
83. th anniversary of aldosterone. J Clin Endocrinol Metab. 2003;88:2364-2372. doi:10.1210/jc.2003-030490.
84. Hollenberg NK, Moore T, Shoback D, Redgrave J, Rabinowe S, Williams GH. Abnormal renal sodium handling in essential hypertension. Relation to failure of renal and adrenal modulation of responses to angiotensin II. Am J Med. 1986;81:412-418.
85. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, Hollenberg NK. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest. 1983;72:2115-2124. doi:10.1172/JCI111176.
86. Williams GH, Dluhy RG, Lifton RP, Moore TJ, Gleason R, Williams R, Hunt SC, Hopkins PN, Hollenberg NK. Non-modulation as an intermediate phenotype in essential hypertension. Hypertension. 1992;20:788-796.
87. Williams GH, Hollenberg NK, Hopkins PM, Jeunemaitre X. The role of intermediate phenotypes in essential hypertension: non-modulation as a model. Endocr Res. 1996;22:675-680.
88. Williams GH, Fisher ND, Hunt SC, Jeunemaitre X, Hopkins PN, Hollenberg NK. Effects of gender and genotype on the phenotypic expression of nonmodulating essential hypertension. Kidney Int. 2000;57:1404-1407. doi:10.1046/j.1523-1755.2000.00982.x.
89. Genest J, Lemieux G, Davignon A, Koiw E, Nowaczynski W, Steyermark P. Human arterial hypertension: a state of mild chronic hyperaldosteronism? Science. 1956;123:503-505.
90. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351:33-41. doi:10.1056/NEJMoa033263.
91. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008;51:432-439. doi:10.1161/HYPERTENSIONAHA.107.103267.
92. Václavík J, Sedlák R, Plachy M, Navrátil K, Plásek J, Jarkovsky J, Václavík T, Husár R, Kociánová E, Táborsky M. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069-1075. doi:10.1161/HYPERTENSIONAHA.111.169961.
93. Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol. 1997;17:1152-1156.
94. Park JB, Schiffrin EL. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens. 2002;15:164-169.
95. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-510.
96. Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, Ménard J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011;124:1945-1955. doi:10.1161/CIRCULATIONAHA.111.029892.
97. Sadée W, Riegelman S, Jones SC. Plasma levels of spirolactones in the dog. J Pharm Sci. 1972;61:1129-1132.
98. Sadée W, Riegelman S, Jones SC. Disposition of tritium-labeled spirolactones in the dog. J Pharm Sci. 1972;61:1132-1135.
99. Sadée W, Dagcioglu M, Schröder R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther. 1973;185:686-695.
100. Schröder R, Schüren KP, Biamino G, Dennert J, Meyer V, Sadée W. [Effect of aldactone on the dynamics and contractility of the heart]. Verh Dtsch Ges Kreislaufforsch. 1971;37:438-445.
101. Delyani JA. Anti-aldosterone therapy in the treatment of heart failure: new thoughts on an old hormone. Expert Opin Investig Drugs. 1998;7:753-759. doi:10.1517/13543784.7.5.753.
102. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. 2000;57:1408-1411. doi:10.1046/j.1523-1755.2000.00983.x.
103. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. doi:10.1056/NEJM199909023411001.
104. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. doi:10.1056/NEJMoa030207.
105. Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2010;12:617-622. doi:10.1093/eurjhf/hfq049.
106. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21. doi:10.1056/NEJMoa1009492.
107. Markowitz M, Messineo F, Coplan NL. Aldosterone receptor antagonists in cardiovascular disease: a review of the recent literature and insight into potential future indications. Clin Cardiol. 2012;35:605-609. doi:10.1002/clc.22025.
108. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz. 2000;25:299-306.
109. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004;110:558-565. doi:10.1161/01.CIR.0000138680.89536.A9.
110. Grandi AM. Antihypertensive therapy: role of aldosterone antagonists. Curr Pharm Des. 2005;11:2235-2242.
111. Venco A, Grandi AM. [Aldosterone blockade in essential hypertension]. Ital Heart J. 2005;6(suppl 1):34S-42S.
112. Desai AS, Lewis EF, Li R, Solomon SD, Assmann SF, Boineau R, Clausell N, Diaz R, Fleg JL, Gordeev I, McKinlay S, O'Meara E, Shaburishvili T, Pitt B, Pfeffer MA. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011;162:966-972.e10. doi:10.1016/j.ahj.2011.09.007.
113. Shah SJ, Heitner JF, Sweitzer NK, et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013;6:184-192. doi:10.1161/CIRCHEARTFAILURE.112.972794.
114. Pitt B, Pfeffer MA, Assmann SF, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-1392. doi:10.1056/NEJMoa1313731.
115. Shah NC, Pringle SD, Donnan PT, Struthers AD. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure. J Hypertens. 2007;25:2345-2351. doi:10.1097/HJH.0b013e3282e9a72d.
116. Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025-3033. doi:10.1161/CIRCULATIONAHA.104.503706.
117. Suzuki S, Ohkusa T, Sato T, Yoshida M, Yasui K, Miwa K, Lee JK, Yano M, Kodama I, Matsuzaki M. Effects of aldosterone on Cx43 gap junction expression in neonatal rat cultured cardiomyocytes. Circ J. 2009;73:1504-1512.
118. Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6:261-273. doi:10.1038/nrneph.2010.30.
119. Toda N, Nakanishi S, Tanabe S. Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications. Br J Pharmacol. 2013;168:519-533. doi:10.1111/j.1476-5381.2012.02194.x.
120. Schmitt M, Gunaruwan P, Frenneaux MP. Rapid nongenomic aldosterone effects in the human forearm? Hypertension. 2004;43:e1; author reply e2.